• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by MyMD Pharmaceuticals, Inc.

    MyMD Pharmaceuticals Announces Corporate Rebranding to New Name TNF Pharmaceuticals, Inc.
    From MyMD Pharmaceuticals, Inc.
    Via Business Wire
    Tickers MYMD
    MyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical Officer
    From MyMD Pharmaceuticals, Inc.
    Via Business Wire
    Tickers MYMD
    MyMD Pharmaceuticals Secures Strategic Investments
    From MyMD Pharmaceuticals, Inc.
    Via Business Wire
    Tickers MYMD
    MyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing
    From MyMD Pharmaceuticals, Inc.
    Via Business Wire
    Tickers MYMD
    MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing
    From MyMD Pharmaceuticals, Inc.
    Via Business Wire
    Tickers MYMD
    MyMD Pharmaceuticals Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis
    From MyMD Pharmaceuticals, Inc.
    Via Business Wire
    Tickers MYMD
    MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD™, Reduced Acute Inflammatory Pain
    From MyMD Pharmaceuticals, Inc.
    Via Business Wire
    Tickers MYMD
    MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-α Market Disrupter, at BioFuture 2023
    From MyMD Pharmaceuticals, Inc.
    Via Business Wire
    Tickers MYMD
    FDA Accepts MyMD Pharmaceuticals’ Investigational New Drug Application (IND) for Phase 2 Study of oral TNF-α inhibitor MYMD-1® in Rheumatoid Arthritis (RA)
    From MyMD Pharmaceuticals, Inc.
    Via Business Wire
    Tickers MYMD
    MyMD Pharmaceuticals to Hold Conference Call Today to Discuss Phase 2 Trial Results
    From MyMD Pharmaceuticals, Inc.
    Via Business Wire
    Tickers MYMD
    MyMD Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral TNF-α Inhibitor MYMD-1® in Sarcopenia/Age-Related Frailty
    From MyMD Pharmaceuticals, Inc.
    Via Business Wire
    Tickers MYMD
    MyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan
    From MyMD Pharmaceuticals, Inc.
    Via Business Wire
    Tickers MYMD
    MyMD Pharmaceuticals® and Charles River Present Positive Data for Next Generation, Oral TNF-α Inhibitor MYMD-1® in Rheumatoid Arthritis
    From MyMD Pharmaceuticals, Inc.
    Via Business Wire
    Tickers MYMD
    MyMD Joins LOT Network in Effort to Protect Company and Shareholders from Patent Trolls
    From MyMD Pharmaceuticals, Inc.
    Via Business Wire
    Tickers MYMD
    MyMD Announces U.S. Drug Enforcement Administration (DEA) Determines Supera-CBD™ is not a Controlled Substance or Listed Chemical
    From MyMD Pharmaceuticals, Inc.
    Via Business Wire
    Tickers MYMD
    MyMD Pharmaceuticals® Announces Upcoming Presentation of Preclinical Rheumatoid Arthritis Data for Oral TNF-α Inhibitor MYMD-1® at the Society of Toxicology 2023 Annual Meeting
    From MyMD Pharmaceuticals, Inc.
    Via Business Wire
    Tickers MYMD
    MyMD Announces $15 Million Offering with Existing Investors
    From MyMD Pharmaceuticals, Inc.
    Via Business Wire
    Tickers MYMD
    ADDING MULTIMEDIA MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022
    From MyMD Pharmaceuticals, Inc.
    Via Business Wire
    Tickers MYMD
    MyMD Pharmaceuticals® Announces Upcoming Presentation of Late-Breaking Data for MYMD-1® at the 2022 British Society for Immunology (BSI) Congress
    From MyMD Pharmaceuticals, Inc.
    Via Business Wire
    Tickers MYMD
    MyMD Pharmaceuticals Announces Publication of Phase 1 Data for oral TNF-alpha Inhibitor MYMD-1® in Peer-Reviewed Journal Drug Research
    From MyMD Pharmaceuticals, Inc.
    Via Business Wire
    Tickers MYMD
    MyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan
    From MyMD Pharmaceuticals, Inc.
    Via Business Wire
    Tickers MYMD
    MyMD Pharmaceuticals Receives Grant From European Patent Office for Supera-CBD™ Compound
    From MyMD Pharmaceuticals, Inc.
    Via Business Wire
    Tickers MYMD
    Data Showing MyMD Pharmaceuticals’ MYMD-1® May Extend Life and Improve Health Published in the Journal of Gerontology: Biological Sciences
    From MyMD Pharmaceuticals, Inc.
    Via Business Wire
    Tickers MYMD
    MyMD Pharmaceuticals® Advances Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan
    From MyMD Pharmaceuticals, Inc.
    Via Business Wire
    Tickers MYMD
    MyMD Pharmaceuticals to Collaborate with Bascom Palmer Eye Institute to Study MYMD-1 in Ophthalmic Conditions
    From MyMD Pharmaceuticals, Inc.
    Via Business Wire
    Tickers MYMD
    MyMD Pharmaceuticals Advances Phase 2 Multi-Center Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan
    From MyMD Pharmaceuticals, Inc.
    Via Business Wire
    Tickers MYMD
    MyMD Pharmaceuticals’ Lead Compound MYMD-1 Demonstrates Superior Anti-inflammatory Effects over Top-Selling Therapies in a Pivotal Preclinical Model of Rheumatoid Arthritis
    From MyMD Pharmaceuticals, Inc.
    Via Business Wire
    MyMD Pharmaceuticals Accelerates Pace of New Patient Dosing in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan
    From MyMD Pharmaceuticals, Inc.
    Via Business Wire
    Tickers MYMD
    MyMD Pharmaceuticals Announces Live Appearance on Cheddar News Network Today March 24
    From MyMD Pharmaceuticals, Inc.
    Via Business Wire
    Tickers MYMD
    MyMD Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan
    From MyMD Pharmaceuticals, Inc.
    Via Business Wire
    Tickers MYMD
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.